Department of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Department of Endocrinology and Metabolism, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Mutat Res Genet Toxicol Environ Mutagen. 2024 Aug-Sep;898:503797. doi: 10.1016/j.mrgentox.2024.503797. Epub 2024 Jul 18.
Papillary thyroid carcinoma (PTC) is a common endocrine cancer with a good prognosis. Radioactive iodine is thought to be useful for individuals who have had a total or almost total thyroidectomy, but its effects are still controversial. The effects of radioactive iodine-131 (I-131) treatment on oxidative and chromosomal damage in PTC patients were examined in this study, which was carried out with 16 patients newly diagnosed with PTC and 20 healthy control subjects with similar age and gender. Blood samples were taken from patients with PTC at five sampling times (before total thyroidectomy, after total thyroidectomy, and seven days, six months, and one year after treatment) and from control subjects. The cytokinesis block micronucleus cytome (CBMN-cyt) assay parameters in peripheral blood lymphocytes of patients with PTC and controls were evaluated and plasma 8-hydroxydeoxyguanosine (8-OHdG) levels were measured. Furthermore, genome instability and oxidative DNA damage in peripheral blood lymphocytes and plasma of patients with PTC were evaluated before total thyroidectomy (n=16), after total thyroidectomy (before I-131 treatment) (n=16), seven days (n=10), six months (n=5), and one year after treatment (n=5). The numbers of CBMN-cyt assay parameters (micronucleus; MN and nucleoplasmic bridges; NPB) and 8-OHdG levels in patients with PTC were determined to be significantly higher than in those of the control subjects and these values significantly decreased after total thyroidectomy (before I-131 treatment). While the number of MN, apoptotic, and necrotic cells increased after I-131 treatment, it significantly decreased after six months and one year after treatment. The results achieved in this study suggest that I-131 treatment may pose a threat to cells and that radioactive iodine therapy should be avoided (if possible) for patients with PTC after total thyroidectomy.
甲状腺乳头状癌（PTC）是一种常见的内分泌癌，预后良好。放射性碘被认为对已接受全甲状腺切除术或几乎全甲状腺切除术的个体有用，但它的作用仍存在争议。本研究检查了放射性碘-131（I-131）治疗对 PTC 患者氧化和染色体损伤的影响，该研究纳入了 16 名新诊断为 PTC 的患者和 20 名年龄和性别相似的健康对照者。在五个时间点采集 PTC 患者的血液样本（全甲状腺切除术前、全甲状腺切除术后，以及治疗后 7 天、6 个月和 1 年）和对照者的血液样本。评估了 PTC 患者和对照者外周血淋巴细胞的胞质阻滞微核细胞（CBMN-cyt）检测参数，并测量了血浆 8-羟基脱氧鸟苷（8-OHdG）水平。此外，在全甲状腺切除术（n=16）前、全甲状腺切除术（I-131 治疗前）（n=16）后、7 天（n=10）、6 个月（n=5）和治疗后 1 年（n=5）时，评估了 PTC 患者外周血淋巴细胞和血浆中的基因组不稳定性和氧化 DNA 损伤。结果显示，PTC 患者的 CBMN-cyt 检测参数（微核；MN 和核质桥；NPB）数量和 8-OHdG 水平明显高于对照组，且全甲状腺切除术后（I-131 治疗前）这些数值显著降低。虽然 I-131 治疗后 MN、凋亡和坏死细胞的数量增加，但治疗后 6 个月和 1 年时，这些数值显著降低。本研究结果表明，I-131 治疗可能对细胞构成威胁，对于全甲状腺切除术后的 PTC 患者，应避免（如果可能的话）进行放射性碘治疗。
